Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Open Access
- 1 January 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (1), e10
- https://doi.org/10.1136/annrheumdis-2020-217549
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Clinical Characteristics of Covid-19 in ChinaThe New England Journal of Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapiesAnnals Of The Rheumatic Diseases, 2020
- Covid-19: risk factors for severe disease and deathBMJ, 2020
- Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivistsIntensive Care Medicine, 2020
- Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendationsRMD Open, 2019
- Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disordersAutoimmunity Reviews, 2018
- The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune diseaseBMC Musculoskeletal Disorders, 2014
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Arthritis Research & Therapy, 2011